Osteoprotegerin Gene Polymorphisms in Men with Coronary Artery Disease
Muhidien Soufi,
Michael Schoppet,
Alexander M. Sattler,
Matthias Herzum,
Bernhard Maisch,
Lorenz C. Hofbauer and
Juergen R. Schaefer
Departments of Internal Medicine and Cardiology (M.So., M.Sc., A.M.S., M.H., B.M., J.R.S.), and Gastroenterology, Endocrinology, and Metabolism (L.C.H.), Philipps University, D-35033 Marburg, Germany
Address all correspondence and requests for reprints to: Dr. Michael Schoppet, Department of Internal Medicine and Cardiology, Philipps University, Baldingerstrasse, D-35033 Marburg, Germany. E-mail: schoppet{at}mailer.uni-marburg.de.
Osteoprotegerin (OPG) antagonizes receptor activator of nuclearfactor-B ligand (RANKL), the principal regulator of osteoclasts.Of note, OPG-deficient mice display osteoporosis and arterialcalcification. Recently, OPG gene polymorphisms have been associatedwith osteoporosis and early predictors of cardiovascular disease.In this study, we examined OPG gene polymorphisms in 468 menwho had absence of coronary artery disease (CAD) or single-,double-, or triple-vessel disease on coronary angiography. Denaturinggradient gel electrophoresis followed by DNA sequencing revealednucleotide substitutions 149 TC, 163 AG, 209 GA, 245 TG, 950TC (all promoter), 1181 GC (exon 1), and 6890 AC (intron 4),respectively. Although single polymorphisms were not associatedwith CAD, linkage of polymorphisms 950 and 1181 revealed thathaplotypes were overrepresented in men with CAD (2 = 17.05;P = 0.03) with an increased risk of CAD in carriers of genotypes950 TC/1181 GC and 950 CC/1181 CC (odds ratio, 1.67; 95% confidenceinterval, 1.022.72; P = 0.04). Furthermore, serum OPGlevels were correlated with the presence of a C allele at position950 (P = 0.02). In summary, linkage of genetic variations ofthe OPG gene at positions 950 and 1181 may confer an increasedrisk of CAD in Caucasian men.
This work was supported by a Heisenberg fellowship from theDeutsche Forschungsgemeinschaft (to L.C.H.; Ho 1875/3-1 andHo 1875/4-1).
C. Hagedorn, R. Telgmann, C. Dordelmann, B. Schmitz, S. Hasenkamp, F. Cambien, M. Paul, E. Brand, and S.-M. Brand-Herrmann Identification and Functional Analyses of Molecular Haplotypes of the Human Osteoprotegerin Gene Promoter
Arterioscler Thromb Vasc Biol,
October 1, 2009;
29(10):
1638 - 1643.
[Abstract][Full Text][PDF]
G. Zauli, F. Corallini, F. Bossi, F. Fischetti, P. Durigutto, C. Celeghini, F. Tedesco, and P. Secchiero Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo
Blood,
July 15, 2007;
110(2):
536 - 543.
[Abstract][Full Text][PDF]
J. R. Crouse III Thematic review series: Patient-Oriented Research. Imaging atherosclerosis: state of the art
J. Lipid Res.,
August 1, 2006;
47(8):
1677 - 1699.
[Abstract][Full Text][PDF]
P. Collin-Osdoby Regulation of Vascular Calcification by Osteoclast Regulatory Factors RANKL and Osteoprotegerin
Circ. Res.,
November 26, 2004;
95(11):
1046 - 1057.
[Abstract][Full Text][PDF]